title: Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction.
abstract: The currently recommended first-line treatments of erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i), for example sildenafil, are efficacious in many patients with ED of vascular origin, but this therapy is insufficient in approximately 30-40% of men with ED where there is also a neuronal affection. There is a demand of novel approaches to treat the condition. We review the possibility of modulating the dopaminergic pathways to improve erectile function. Dopamine D1(D1, D5)- and D2(D2-D4)-like receptors in the paraventricular area, the medial pre-optic area, the spinal cord, and in the erectile tissue are involved in erection, and several agonists developed for the treatment of Parkinson's disease are associated with increased libido. A therapeutic window for the treatment of ED was found by sublingual administration of the general dopamine receptor agonist apomorphine, but it failed mainly due to less efficacy on erectile function compared with PDE5i. To avoid the dose-limiting side effects mediated by D2receptors, nausea and emesis, dopamine D4receptor agonists were developed, and they induce erection in rodents, but these drugs were never introduced clinically. The β-lactamase inhibitor clavulanic acid increases dopamine and serotonin and was found to increase sexual arousal and erections, but the dose-response curve is bell-shaped. Bupropion has selectivity for inhibition of the dopamine reuptake transporter and can be used to alleviate sexual symptoms caused by other antidepressant medication, hence providing an interesting approach to treat ED. In summary, modulation of the dopaminergic pathways provides a possibility to improve the treatment of ED.
authors.affiliation: Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus C, Denmark. us@biomed.au.dk.
authors.forename: Ulf
authors.initials: U
authors.lastname: Simonsen
authors.affiliation: Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus C, Denmark.|Department of Biomedical Science, Faculty of Veterinary Science, Central University of Venezuela, Maracay, Bolivarian Republic of Venezuela.
authors.forename: Simon
authors.initials: S
authors.lastname: Comerma-Steffensen
authors.affiliation: Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus C, Denmark.
authors.forename: Karl-Erik
authors.initials: KE
authors.lastname: Andersson
mesh_terms: D000818:Animals; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D059290:Dopaminergic Neurons / Q000187:drug effects* / Q000378:metabolism; D016903:Drug Monitoring; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005837:Genitalia, Male / Q000187:drug effects* / Q000294:innervation / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D008297:Male; D008954:Models, Biological; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D018491:Dopamine Agonists; D004298:Dopamine